Saphenion®: Faktencheck VenaSeal – Cyanoacrylatkleber bei Krampfadern

Saphenion®: Faktencheck VenaSeal – Cyanoacrylatkleber bei Krampfadern
Werden in der Chirurgie Kleber eingesetzt, handelt es sich nahezu immer um Cyanoacrylate. Diese wurden erstmals 1949 synthetisiert, in 1959 wurde die extrem hohe Klebkraft festgestellt und bereits 1960 wurden sie erstmals als Biokleber eingesetzt.

Saphenion®: Fact check VenaSeal – cyanoacrylate adhesive for varicose veins
When adhesives are used in surgery, they are almost always cyanoacrylates. These were first synthesized in 1949, their extremely high adhesive strength was discovered in 1959 and they were first used as bioadhesives as early as 1960.

Saphenion®: Long-time results of vein glue

Saphenion®: long-time results of vein glue – has been published by us in regular succession for 10 years and aims to compare international publications on the subject with our own experiences and to remain meaningful. Our patients are now very well informed about this therapy method for varicose veins, which has been offered for 13 years.

After 152 months of use, we have so far treated 2215 patients on 4642 saphenous veins – over 1,1 Mio. patients worldwide have now been treated with the vein glue VenaSeal®. In the meantime, we have successfully used the vein glue VenaSeal® to clean the vein system in 67 patients with COVID-19 infection after they have recovered, and have treated 75 patients with ulcera crures of legs successfully.

Saphenion®: Venenkleber bei Krampfadern – wie funktioniert es?

Saphenion®: Venenkleber bei Krampfadern – wie geht es?
Wir haben dazu einen kleinen Film gedreht – mit ein wenig Spaß und Augenzwinkern aber ganz ernsthaftem Hintergrund.

Saphenion®: vein glue: how it`s running … Biscuits and honey as main actors
We have created a short clip – with a little bit of fun and with smile

Saphenion®: Neue Therapieoption

Das RFITT – Verfahren (Radiofrequenzinduzierte Thermotherapie) der ersten und zweiten Generation haben wir seit 2007 an 2800 Stammkrampfadern eingesetzt. Darüber hinaus haben wir dieses System erfolgreich bei der Behandlung von Kniegelenkzysten (sog. Bakerzysten eingeführt.
Das bipolare RFITT Precision System findet auch Anwendung bei: Tumorablation (Leber, Lunge, Niere, Prostata, Brust), Schilddrüse (kalte/ heiße Knoten), Facettengelenksdenervationen und der Therapie des Nasensegels (HNO).

Saphenion®: Vein glue versus radiofrequency therapy – 7 years comparison

Vein glue versus radiofrequency therapy – 7 years: For more than 20 years now, truncal varicose veins has increasingly been treated endovenously with catheter support. It all began with the rather cumbersome VNUS® Closure process and the easier-to-use linear laser. This was followed in 2006/2007 by the bipolar RFITT® catheter and the VNUS® ClosureFast system as well as the radial laser. However, it should be said that following historical medical truth, endovenous sclerotherapy has been developed and used since 1911. And already in the late 20s, many surgeons in Germany used the gluing technique with sugar solutions. Also, Ferdinand Sauerbruch of the Charitè hospital in Berlin was a friend of this method.

Saphenion: SimultanTherapie Krampfader und Baker-Zyste

Saphenion: SimultanTherapie Krampfader und Baker-Zyste? Zugegeben, diese aussergewöhnliche Kombination verschiedener Therapien simultan in einer Sitzung sind eher nicht die Regel. Es ist aber schon erstaunlich häufig, daß wir bei den standardisierten Ultraschall-Untersuchungen der Beinvenen auf der Suche nach Krampfadern auch Baker-Zysten an den Kniegelenken sehen. Nach unseren eigenen Zahlen liegt diese Befundkombination bei ca. 5% aller bei uns untersuchten Patienten vor.

Saphenion: Simultaneous therapy for varicose veins and Baker’s cyst? Admittedly, this extraordinary combination of different therapies simultaneously in one session is not the norm. But it is surprisingly common that we also see Baker’s cysts on the knee joints during standardized ultrasound examinations of the leg veins in search of varicose veins. According to our own figures, this combination of findings is available in approx. 5% of all patients examined by us.